

Original Article

COMPARATIVE STUDY OF ANTIDEPRESSANT-LIKE EFFECT OF THE LEAVES OF *SAPINDUS EMARGINATUS* AND *ACORUS CALAMUS* IN EXPERIMENTAL ANIMAL MODELS

PRIYADARSHINI SHOUGRAKAM, ABHISHEK BHATTACHARJEE, MAYANGLAMBAM MEDHABATI, NGANGOM GUNINDRO

Department of Pharmacology, Regional Institute of Medical Sciences, Imphal, India
Email: drmedhabati@gmail.com

Received: 14 Sep 2020, Revised and Accepted: 17 Nov 2020

ABSTRACT

Objective: Depression is an affective disorder characterized by a change in mood, lack of confidence, lack of interest in surroundings and many natural products that have been tried to treat the disease. The study was aimed to evaluate and compare the antidepressant activity of methanol leaf extract of *Sapindusemarginatus* Vahl. (MESE) and *Acoruscalamus* Linn. (MEAC) in experimental models in albino mice.

Methods: Methanol Extracts of the plants were prepared by soxhlet extraction method. Forced swimming test (FST) and Tail suspension test (TST) models were chosen to evaluate antidepressant activity. Albino mice were selected and divided into six groups of six animals for each experimental model. Group I received 1% gum acacia in distilled water (DW) at a dose of 1 ml/100 g orally. Group II received sertraline-10 mg/kg orally. Group III and IV were administered 200 and 400 mg/kg of MESE respectively. Group V and VI were treated with 200 and 400 mg/kg of MEAC, respectively.

Results: Methanol extracts of *Sapindusemarginatus* and *Acoruscalamus* at the two different doses of 200 and 400 mg/kg demonstrated a significant decrease in immobility time when compared with the control in both animal models. The extracts at the higher dose of 400 mg/kg revealed a significant reduction in immobility time compared to 200 mg/kg of the same extract.

Conclusion: The results suggest that the methanol extracts of *Sapindusemarginatus* Vahl. and *Acoruscalamus* Linn. possess the anticonvulsant activity and justify their use in folk medicine.

Keywords: *Sapindusemarginatus*, *Acoruscalamus*, FST, TST, Antidepressant

© 2021 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (<https://creativecommons.org/licenses/by/4.0/>)
DOI: <https://dx.doi.org/10.22159/ijcpr.2021v13i1.40800>. Journal homepage: <https://innovareacademics.in/journals/index.php/ijcpr>

INTRODUCTION

Depression is an affective disorder characterized by a change in the mood, lack of confidence, lack of interest in surroundings and the severity may range from mild to severe [1]. About 450 million people suffer from mental or behavioral disorders. Depression will become the second leading cause of premature death or disability worldwide by the year 2020. A large percentage of patients suffering from depression respond to the currently available antidepressants, but the extent of improvement is still disappointing because of various side effects and drug tolerance [2]. Till today, there are many unmet clinical needs with respect to the efficacy and adverse effects of the various antidepressants. To address these needs, antidepressants with novel mechanisms and fewer side effects are in great demand [3].

It is a fact that many natural products and synthetically modified natural product derivatives have been successfully developed for clinical use to treat human diseases in almost all therapeutic domains [4]. The treatment and control of diseases by using locally available medicinal plants will continue to play significant roles in medical health care implementation in developing countries [5].

Globally herbal medicines are extensively used due to their therapeutic efficiency and minimum side effects in neurological disorders; therefore, investigations for the search of novel and better-tolerated molecules from plant sources have progressed in recent years demonstrating the pharmacological effectiveness of different plant species in a variety of animal models [6]. However, to the best of our knowledge, there is no single scientific report demonstrating the anti-depressant activity of *Sapindusemarginatus* and *Acoruscalamus*. Current investigation aimed at evaluating the antidepressant potential of *Sapindusemarginatus* and *Acoruscalamus*. Depression represents one of the major health problems among other mood disorders worldwide. The use of

suitable animal models is essential for understanding of the neurobiological basis of mood disorders and is facilitating the approaches for the discovery of novel therapeutic targets. Forced Swim Test (FST) and Tail Suspension Test (TST) are employed as exemplary systems to probe depressing condition in rodents [7].

Immobility or despair behaviour produced in both FST and TST were hypothesized to display animal's hopelessness and low mood (behavioural despair), and are taken as paradigm of depression. This simple behavioural procedure is a widely used test for screening novel antidepressants [7].

There are number of pharmacological studies on *Sapindusemarginatus* and *Acoruscalamus* in the literature. Some studies reported the potentials of the two plants as anticonvulsants. Depression is a mood disorder often accompanied with convulsive disorders in humans. Therefore, we also focused on the evaluation and comparison of the effects of the two plants on depression models.

MATERIALS AND METHODS

Approval of institutional animal ethics committee (IAEC)

The study was conducted in the Department of Pharmacology, Regional Institute of Medical Sciences, Imphal, after getting approval of the Institutional Animal Ethics committee, RIMS, Imphal (No.1596/GO/a/12/CPCSEA).

Requirements

Albino mice, polypropylene cages, feeding tubes, Plexiglas cylinder (height-20 cm, diameter-15 cm), distilled Water, towels, warming lamp, horizontal ring-stand bar, adhesive tape, stopwatch, marker, measuring tape, petroleum ether, methanol, soxhlet apparatus, plant extracts, mixer grinder, evaporating dish, gum

acacia and sertraline tablet (Intas Pharmaceutical, Selaqui, Dehradun, B. No DT2703).

Preparation of plant extract

Sapindusemarginatus Vahl. and *Acoruscalamus* Linn. were collected from Imphal valley in the month of August-September 2016. The plants were identified and authenticated by Prof. PK Singh, Department of Life Sciences, Manipur University (Acc. no. MUMP-0197 and MUMP-1423).

The methanol extract of *Sapindusemarginatus* (MESE) and *Acoruscalamus* (MEAC) were prepared by the method described by Lin J *et al.* [8]. The leaves were cleaned, air-dried under the shade and powdered by a mixture grinder. The powdered materials of the two plants were extracted separately with methanol after defatting with petroleum ether using Soxhlet apparatus. The extracts obtained were evaporated, scraped out and stored in an airtight container. The yield obtained was 10% and 6% for *Sapindusemarginatus* and *Acoruscalamus*, respectively [8].

Phytochemical screening

The preliminary phytochemical tests of the plant extracts were carried out using standard procedures [9,10].

Experimental animals

Healthy albino mice of either sex weighing approximately 25-30 g were obtained from the Animal House, RIMS, Imphal. These animals were acclimatized to the laboratory conditions for 7 d before the experiment. The animals were housed in the departmental animal room in groups in polypropylene cages at room temperature with natural light and dark cycle. They were housed in groups of 6 animals per cage and maintained on a standard animal diet with water *ad libitum*.

Acute toxicity testing

The acute toxicity testing was carried out as per OECD guidelines 423 [11] in albino mice. Three animals were used for each step. The plant extracts i.e. MESE (methanol extract of *Sapindusemarginatus*) and MEAC (methanol extract of *Acoruscalamus*) were administered to the fasted mice at a dose of 300 mg/kg p. o. and observed once in every 30 min during the first 24 h and thereafter, daily for 14 d. As there was no mortality, the procedure was repeated with a higher dose of 2000 mg/kg, and the animals were observed for mortality and toxic symptoms. It was observed that the dose of 2000 mg/kg p. o. of the plant extracts caused no mortality or toxic symptoms in the tested animals and the dose was considered safe. Two doses of 200 mg/kg (1/10th of the maximum test dose) and 400 mg/kg (1/5th of the maximum test dose) of the plant extracts were selected as working doses for the experiment.

Selection of animals

Animals were subjected to a pre-test assessment. For the Forced swim test (FST), mice were placed gently and slowly by holding its tail in the water inside a vertical Plexiglas cylinder containing fresh water (25 ± 1 °C) upto a height of 12 cm for 2 min. Thirty-six mice showing vigorous movement to escape from the water during the session were selected.

For Tail suspension test (TST), the animals were suspended from a horizontal bar 30 cm above the surface with an adhesive tape placed 2 cm away from the tip of the tail for 2 min. Thirty-six mice showing alternating agitation and immobility during the session were selected.

Experimental design

For both the FST and TST, selected mice were divided into six groups (I, II, III, IV, V and VI) of 6 animals each. The mice in group I (Control) were given 1% gum acacia in distilled water (DW) at the dose of 1 ml/100 g orally. The group II (Standard) animals were treated with sertraline-10 mg/kg. The mice in group III and IV were made to receive 200 and 400 mg/kg of MESE, respectively. The group V and VI mice were treated with 200 and 400 mg/kg of MEAC, respectively. Sertraline and the test drugs i.e. MESE and MEAC were

suspended in 1% gum acacia in D/W in such a way that 1 ml of the suspension contained the calculated doses of the drugs and given orally (p. o.) once daily using feeding tubes for 7 consecutive days. After overnight fasting on the next day, mice in each group were evaluated after 1h of drug administration. The experiments were carried out in a quiet room under controlled light conditions between 11:00 a. m. and 3:00 p. m.

Procedure

Forced swim test (FST)

The principle adopted by Porsolt *et al.* [12] was followed. The animals were forced to swim for a period of 6 min inside a vertical plexiglas cylinder containing freshwater (25 ± 1 °C) upto a height of 12 cm. The duration of immobility that alternates with phase of enhanced motor activity was recorded during the last 4 min of the total testing period. During initial 2 min of the test, there were vigorous swimming activities and attempts of trying to escape by diving or climbing the walls of the cylinder. Duration of immobility in the control and various treatment groups were compared. Decrease in the duration of immobility was considered as an index of antidepressant activity. The animal was judged to be immobile whenever it remains floating passively in the water in a slight hunched but upright position with its nose just above the surface. Following the swimming session, the mice were taken out of water, mopped with towels and kept warmed using lamps to prevent hypothermia before being returned to the cages. Water in the cylinder was changed after each swimming session.

Tail suspension test

The test was performed according to the method described by Duszczyk M *et al.* [13]. The animals were hung by the tail from a horizontal ring-stand bar 30 cm above the surface with an adhesive tape placed 2 cm away from the tip of the tail. The duration of immobility was observed for a period of 6 min. Mice were considered immobile only when they hung passively and completely motionless. The period of immobility in the control and various treated groups were compared. The decrease in the immobility period was considered as an index of antidepressant activity.

Analysis of results

The results were expressed as mean ± standard deviation (SD) and analyzed by One-way analysis of variance (ANOVA) followed by Bonferroni test. P-value less than 0.05 was considered significant. IBM SPSS statistics version 21 was used for the analysis.

RESULTS

Phytochemical screening

The preliminary qualitative phytochemical analysis of methanol extract of *Sapindusemarginatus* revealed the presence of alkaloids, carbohydrates, flavonoids, saponins, tannins, gums and proteins, while the extract of *Acoruscalamus* revealed the presence of flavonoids, saponins, tannins, alkaloids and starch.

Forced swim test

The mean duration of immobility (sec) in various groups treated with control, Sertraline-10 mg/kg, MESE-200 mg/kg, MESE-400 mg/kg, MEAC-200 mg/kg and MEAC-400 mg/kg were 177.67 ± 15.83, 56.83 ± 4.75, 93.67 ± 13.11, 54.33 ± 17.61, 110 ± 6.38 and 63 ± 13.08 respectively. In the groups treated with Sertraline-10 mg/kg, 200 and 400 mg/kg of MESE and MEAC, the duration of the immobility decreased significantly (P < 0.001) when compared with the control. The period of immobility in the groups treated with 400 mg/kg of MESE and MEAC and Sertraline-10 mg/kg were comparable. However, the Sertraline treated group demonstrated significantly shorter (P < 0.001) period of immobility when compared with the groups treated with 200 mg/kg of MESE and MEAC. The extracts at the dose of 400 mg/kg demonstrated significantly (P < 0.001) shorter duration of immobility when compared with their lower doses i.e. 200 mg/kg. In the MESE-400 mg/kg treated group, the immobility period was significantly (P < 0.001) less when compared with the groups treated with MEAC-200 mg/kg, and the so also duration of immobility was shortened significantly (P < 0.001) in the MEAC -400

mg/kg treated group when compared with MESE-200 mg/kg treated group. However, the immobility periods in the group treated with equal doses of the extracts were comparable (table 1)

Table 1: Effect on the duration of immobility in forced swim test (FST)

Treatment group	Duration of immobility(second)		
I. Control-1%gum acacia susp.	177.67±15.83		
II. Sertraline-10 mg/kg	56.83±4.75 ^{††}		
II. MESE-200 mg/kg	93.67±13.11 [*]		
V. MESE-400 mg/kg	54.33±17.61 ^{*#}		
V. MEAC-200 mg/kg	110.00±6.38 [*]		
I. MEAC-400 mg/kg	63.00±13.08 ^{*#§}		
One way ANOVA	F83.1	Df35	P<0.001

Values are mean±SD, n=6; ^{††}P<0.001 when compared with control, ^{*}P<0.001 when compared with MESE-200 mg/kg and MEAC-200 mg/kg, [#]P<0.001 when compared with 200 mg/kg of same extract, [#]P<0.001 when compared with MEAC-200 mg/kg, [§]P<0.01 when compared with MESE-200 mg/kg. (One way ANOVA followed by Bonferroni test).

Tail suspension test

The mean duration of immobility (sec) in various groups treated with control, Sertraline-10 mg/kg, MESE-200 mg/kg, MESE-400 mg/kg, MEAC-200 mg/kg and MEAC-400 mg/kg were 166.33±4.50, 57.83±5.60, 144.83±8.28, 106.67±7.50, 153.50±8.46 and 114±4.94 respectively. The durations of immobility were significantly reduced in the Sertraline, MESE and MEAC treated groups when compared with the control group. The Sertraline treated group shortens the period of immobility significantly (P<0.001) when compared with the groups treated with 200 and

400 mg/kg of the two extracts. The group receiving 400 mg/kg of the extracts demonstrated a significantly shorter (P<0.001) duration of immobility when compared with their lower doses i.e. 200 mg/kg. In the MESE-400 mg/kg treated group, the immobility period was significantly (P<0.001) decreased when compared with the group treated with MEAC-200 mg/kg. Significantly shorten (P<0.01) immobility time was also observed in MEAC-400 mg/kg treated group when compared with the MESE-200 mg/kg treated group. The immobility periods in the group treated with equal doses of the extracts were comparable.

Table 2: Effect on duration of immobility in tail suspension test

Treatment group(p. o.)	Duration of immobility(second)		
I. Control-1%gum acacia susp.	166.33±4.50		
II. Sertraline-10 mg/kg	57.83±5.60 ^{††}		
II. MESE-200 mg/kg	144.83±8.28 [*]		
V. MESE-400 mg/kg	106.67±7.50 ^{*#}		
V. MEAC-200 mg/kg	153.50±8.46 ^{**}		
I. MEAC-400 mg/kg	114±4.94 ^{*#§}		
One way ANOVA	F208.2	Df35	P<0.001

Values are mean±SD, n=6, ^{††}P<0.001, ^{*}P<0.05 when compared with control, [†]P<0.001 when compared with MESE and MEAC treated groups, [#]P<0.001 when compared with 200 mg/kg of the same extracts, [#]P<0.001 when compared with MEAC-200 mg/kg, [§]P<0.01 when compared with MESE-200 mg/kg. (One way ANOVA followed by Bonferroni test).

DISCUSSION

Mice are commonly used rodents which are small, easily housed and maintained. Interestingly, the genetic, biological and behavioural characteristics of the rodents closely resemble to those of humans. Various human disorders, including behavioural disorders and seizures are studied in suitable mice models [13].

The Forced swim test (FST) and Tail suspension test (TST) are widely accepted behavioural models for the assessment of antidepressant activity. It is well known that many antidepressant drugs are able to reduce immobility time in rodents in the above models [14]. The forced swimming induced state of immobility in animals is claimed to represent a condition similar to human depression [15]. However, TST is considered to have greater pharmacological sensitivity than FST for antidepressants acting through selective inhibition of serotonin reuptake [16]. Both the methanol extracts of *Sapindusemarginatus* and *Acoruscalamus* at the two different doses of 200 and 400 mg/kg demonstrated decreased immobility time when compared with the control in both animal models and this observation is strongly suggestive of their antidepressant property. The extracts at the higher dose of 400 mg/kg is more effective than the 200 mg/kg dose. However, the antidepressant activity was not significantly different between similar doses of the plant extracts.

The biochemical basis of depression suggests that the disorder is linked with functional deficiency of the brain monoaminergic transmitters like norepinephrine (NE), 5-HT (serotonin) and/or

dopamine (DA) [17]. Practically all antidepressants affect monoaminergic transmission in the brain in one way or the other and a large number of antidepressants with effects on reuptake/metabolism of biogenic amines, and on pre/post-junctional aminergic/cholinergic receptors have also been known. The standard drug, sertraline is a popular antidepressant that blocks the reuptake of serotonin into the neurons resulting to increased serotonin availability at its receptors in the CNS [18].

The qualitative analysis of methanol extract of *Sapindusemarginatus* and *Acoruscalamus* revealed the presence of phytochemicals such as alkaloids, flavonoids, saponins, tannins and carbohydrates. The flavonoids such as hesperidin, naringenin, quercetin, and astilbin are reported to display antidepressant-like activity in animal experimental models [19]. Many flavonoids are inhibitors of MAO-A and-B [20].

Therefore, it may be assumed that the presence of the flavonoids in the two plant extracts might have contributed to the antidepressant activity.

CONCLUSION

The findings of our study reveal that the methanol extracts of *Sapindusemarginatus* and *Acoruscalamus* leaves possess antidepressant activity. Further studies with isolated biologically active principles of the plants in different models of depression will be more meaningful and interesting.

ACKNOWLEDGEMENT

The authors respectfully acknowledge the contribution of Dr. PK Singh, Professor, Department of Life Sciences, Manipur University in the authentication of the study plants.

AUTHORS CONTRIBUTIONS

All the authors have contributed equally.

FUNDING

Nil

CONFLICTS OF INTERESTS

Declared none

REFERENCES

- Singh JN, Kumar S, Rana AC. Antidepressant activity of methanolic extract of *FoeniculumVulgare* (Fennel) fruits in experimental animal models. *J Appl Pharm Sci* 2013;3:65-70.
- Onasanwo SA, Chatterjee M, Palit G. Antidepressant and anxiolytic potentials of dichloromethane fraction from *Hedrantherabarberi*. *Afr J Biomed Res* 2010;13:76-81.
- Yu L, Jiang X, Liao M, Ma R, Yu T. Antidepressant-like effect of tetramethylpyrazine in mice and rats. *Neurosci Med* 2011;2:142-8.
- Newman DJ, Cragg GM. Natural products as sources of new drugs over the last 25 y. *J Nat Prod* 2007;70:461-77.
- Coolborn AF, Bolatito B. Antibacterial and phytochemical evaluation of three medicinal plants. *J Nat Prod* 2010;3:27-34.
- Zhang ZJ. Therapeutic effects of herbal extracts and constituents in animal models of psychiatric disorders. *Life Sci* 2004;75:1659-99.
- Alamgeer MNHM, Mushtaq MN, Bashir S, Ghumman SA, Akram M, Khan HU, *et al*. Evaluation of some central nervous system (CNS) activities of aqueous methanolic extract of *Paspalidiumflavidum*linn. *J Med Plant Res* 2012;6:3222-7.
- Lin J, Opoku AR, Keller MG, Hutchings AD, Terblanche SE, Jager AK, *et al*. Preliminary screening of some traditional zulu medicinal plants for anti-inflammatory and anti-microbial activities. *J Ethnopharmacol* 1999;68:267-74.
- Kokate CK, Purohit AP, Gokhale SB. *Pharmacognosy*. 45th ed. Pune: NiraliPrakashan; 2009.
- Shah B, Seth AK. *Textbook of pharmacognosy and phytochemistry*. 2nded. New Delhi: Elsevier; 2014.
- OECD. OECD guidelines for testing of chemicals 423:Acute oral toxicity–acute toxic class method. Paris; 2001. Available from: https://ntp.niehs.nih.gov/iccvm/suppdocs/fedddocs/oecd/ocd_gl423.pdf. [Last accessed on 14 Sep 2018]
- Porsolt R, Bertin A, Jalfre M. Behavioural despair in mice: a primary screening test for antidepressants. *Arch IntPharmacodynTher* 1977;229:327-36.
- Melina R. Why do medical researchers use mice? 2010. Available from: <https://www.livescience.com/32860-why-do-medical-researchers-used-mice.html>. [Last accessed on 12 Sep 2018]
- DuszczykM, Gamczyk M, Ziembowicz A, Boguszewski PM, Łazarewicz JW, Salińska E. Antidepressant-like and anxiolytic-like effects of mild hypobaric hypoxia in mice: possible involvement of neuropeptide Y. *ActaNeurobiolExp(Wars)* 2015;75:364-71.
- CE Renard, E Dailly, DJ David, M Hascoet, M Bourin. Monoamine metabolism changes following the mouse forced swimming test but not the tail suspension test. *FundamClinPharmacol* 2003;17:449-55.
- Cryan JF, Mombereau C, Vassout A. The tail suspension test as a model for assessing antidepressant activity: a review of pharmacological and genetic studies in mice. *NeurosciBiobehav Rev* 2005;29:571-625.
- Bondy B. Pathophysiology of depression and mechanisms of treatment. *Dialogues ClinNeurosci* 2002;4:7-20.
- Tripathi KD. *Essentials of medical pharmacology*. 8thed. New Delhi, Jaypee Brothers Medical Publishers; 2019.
- Hritcu L, Ionita R, Postu PA, Gupta GK, Turkez H, Lima TC, *et al*. Antidepressant flavonoids and their relationship with oxidative stress. *Oxid Med Cell Longev* 2017;1-18. Available from: <https://www.hindawi.com/journals/omcl/2017/5762172/citations/>. [Last accessed 10Sep 2018]
- Jager AK, Saaby L. Flavonoids and the CNS. *Molecules* 2011;16:1471-85.